PE20010580A1 - PHARMACEUTICAL COMPOSITION TO TREAT DIABETES - Google Patents

PHARMACEUTICAL COMPOSITION TO TREAT DIABETES

Info

Publication number
PE20010580A1
PE20010580A1 PE2000000887A PE0008872000A PE20010580A1 PE 20010580 A1 PE20010580 A1 PE 20010580A1 PE 2000000887 A PE2000000887 A PE 2000000887A PE 0008872000 A PE0008872000 A PE 0008872000A PE 20010580 A1 PE20010580 A1 PE 20010580A1
Authority
PE
Peru
Prior art keywords
alkyl
alcoxycarbonyl
carboxyl
pharmaceutical composition
ora
Prior art date
Application number
PE2000000887A
Other languages
Spanish (es)
Inventor
Katsuichi Sudo
Yasuhiko Wada
Yasuo Sugiyama
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PE20010580A1 publication Critical patent/PE20010580A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN SENSIBILIZADOR DE INSULINA EN COMBINACION CON a)UN COMPUESTO I, R1 ES ALQUILO SUSTITUIDO POR OH, FENILSULFONILAMINO, ALQUILSULFONILAMINO, MONOALQUILAMINOSULFONILO, XaRa, -[O(CH2)p-CH(Rb)]qRbb, -O(CH2)r-Rc, Ya-(CH2)s-Rd O JUNTO CON R2 FORMA METILENDIOXILO OPCIONALMENTE SUSTITUIDO POR CARBOXILO, ALCOXICARBONILO, Ra ES H, ALQUILO, Ra ES ALQUILO CUANDO Xa ES S, Rb ES H, ALQUILO, ALCOXICARBONILO, CARBOXILO, Rbb ES ALCOXICARBONILO, CARBOXILO, p ES 0-3; q ES 0-1; Rc ES ALCANOILO, HIDROXILO, CIANO, FENILO, ALQUILAMINOCARBONILO, P(=O)(ORA)(ORA), RA ES H, ALQUILO; r ES 1-4; Ya ES HN, S, Rd ES CARBOXILO, ALCOXICARBONILO; s ES 1-4; R2 ES H, HALOGENO, ALQUILO, OH, ALCOXILO; R3 ES H, ALQUILO; W ES 2-, 3-INDOL; b)UN COMPUESTO IV, R ES UN HIDROCARBURO, HETEROCICLO; Y ES CO, CHOH, NR3; R3 ES ALQUILO; m ES 0-1; n ES 0-2; X ES CH, N; A ES UN ENLACE, HIDROCARBURO; Q ES O, S; R1 ES H, ALQUILO; L Y M SON H DE PREFERENCIA ES PIOGLITAZONA, ROSIGLITAZONA, EN COMBINACION CON 2-[3-(7-CARBOXIMETOXIINDOL-3-IL)-(2R)-2-PROPILAMINO]-(1R)-1-(3-CLOROFENIL)ETANOL. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES, TOLERANCIA A GLUCOSA DISMINUIDA, HIPERLIPIDEMIA, HIPERINSULINEMIA, OBESIDAD, HIPERFAGIA, HIPERTENSION, RETINOPATIA, NEFROPATIA, PARA INHIBIR EL AUMENTO DE PESOREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING AN INSULIN SENSITIZER IN COMBINATION WITH a) A COMPOUND I, R1 IS ALKYL SUBSTITUTED BY OH, PHENYLSULFONYLAMINE, ALKYLSULFONYLAMINE, MONOALKYLAMINES, OR (qRB2) -PUBLPHONYL, Xab) (q) CHULFONYL. , -O (CH2) r-Rc, Ya- (CH2) s-Rd OR TOGETHER WITH R2 METHYLENDIOXYL FORM OPTIONALLY REPLACED BY CARBOXYL, ALCOXYCARBONYL, Ra IS H, ALKYL, Ra IS RENT WHEN Xa IS S, Rb IS H, ALKYL , ALCOXYCARBONYL, CARBOXYL, Rbb IS ALCOXYCARBONYL, CARBOXYL, p IS 0-3; q IS 0-1; Rc IS ALKANOYL, HYDROXYL, CYANE, PHENYL, ALKYLAMINE CARBONYL, P (= O) (ORA) (ORA), RA IS H, ALKYL; r IS 1-4; Ya IS HN, S, Rd IS CARBOXYL, ALCOXYCARBONYL; s IS 1-4; R2 IS H, HALOGEN, ALKYL, OH, ALCOXYL; R3 IS H, ALKYL; W ES 2-, 3-INDOL; b) A COMPOUND IV, R IS A HYDROCARBON, HETEROCICLO; Y IS CO, CHOH, NR3; R3 IS RENT; m IS 0-1; n IS 0-2; X IS CH, N; A IS A LINK, HYDROCARBON; Q IS O, S; R1 IS H, ALKYL; L AND M ARE H OF PREFERENCE IS PIOGLITAZONE, ROSIGLITAZONE, IN COMBINATION WITH 2- [3- (7-CARBOXIMETOXIINDOL-3-IL) - (2R) -2-PROPYLAMINO] - (1R) -1- (3-CHLOROPHENYL) ETHANOL. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF DIABETES, DECREASED GLUCOSE TOLERANCE, HYPERLIPIDEMIA, HYPERINSULINEMIA, OBESITY, HYPERPHAGIA, HYPERTENSION, RETINOPATHY, NEPHROPATIA, TO INHIBIT PYRONIC INCREASE

PE2000000887A 1999-09-03 2000-08-29 PHARMACEUTICAL COMPOSITION TO TREAT DIABETES PE20010580A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25044399 1999-09-03
JP2000056021 2000-02-28

Publications (1)

Publication Number Publication Date
PE20010580A1 true PE20010580A1 (en) 2001-05-25

Family

ID=26539777

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000887A PE20010580A1 (en) 1999-09-03 2000-08-29 PHARMACEUTICAL COMPOSITION TO TREAT DIABETES

Country Status (14)

Country Link
EP (1) EP1212090A2 (en)
KR (1) KR20020063555A (en)
CN (1) CN1372476A (en)
AR (1) AR031674A1 (en)
AU (1) AU6868000A (en)
CA (1) CA2383946A1 (en)
CO (1) CO5180632A1 (en)
HK (1) HK1044711A1 (en)
HU (1) HUP0203285A3 (en)
NO (1) NO20021036L (en)
PE (1) PE20010580A1 (en)
PL (1) PL354295A1 (en)
RU (1) RU2002108346A (en)
WO (1) WO2001017513A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123665T2 (en) 2000-12-26 2007-08-16 Sankyo Co., Ltd. MEDICAL COMPOSITIONS WITH DIURETIC AND INSULIN RESISTANCE TO IMPROVE MEDIUM
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
US6838442B2 (en) 2001-04-04 2005-01-04 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
FR2838968A1 (en) * 2002-04-30 2003-10-31 Lipha ASSOCIATION OF INSULIN AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR TREATING DIABETES
AU2003242245A1 (en) * 2002-06-12 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. Indole, indazole, and benzazole derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005721A1 (en) * 1988-11-14 1990-05-31 The Upjohn Company Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
DE69100282T3 (en) * 1990-02-09 2001-01-11 Upjohn Co USE OF INSULIN-SENSITIZING ACTIVE SUBSTANCES FOR THE TREATMENT OF HYPERTONIA.
CA2206307A1 (en) * 1994-11-29 1996-06-06 Dainippon Pharmaceutical Co., Ltd. Indole derivative

Also Published As

Publication number Publication date
NO20021036D0 (en) 2002-03-01
HUP0203285A3 (en) 2003-02-28
HUP0203285A2 (en) 2003-01-28
HK1044711A1 (en) 2002-11-01
WO2001017513A3 (en) 2001-09-20
AU6868000A (en) 2001-04-10
PL354295A1 (en) 2004-01-12
AR031674A1 (en) 2003-10-01
CO5180632A1 (en) 2002-07-30
NO20021036L (en) 2002-04-26
CN1372476A (en) 2002-10-02
KR20020063555A (en) 2002-08-03
WO2001017513A2 (en) 2001-03-15
EP1212090A2 (en) 2002-06-12
RU2002108346A (en) 2003-11-20
CA2383946A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
RU2312106C2 (en) Substituted 4-alkoxyoxazol derivatives as ppar agonists
KR950702982A (en) Substituted Thiazolidinedione Derivatives
RU2003137825A (en) Pyranoindazoles and their use in the treatment of glaucoma
KR880002834A (en) α-alkyl-4-amino-3-quinolinmethanol and 1- (4-aralkylamino-3-quinolinyl) alkanones, methods for their preparation and use as medicaments
EA200601145A1 (en) TABLET OF SLOW-DIVISION OF INSULIN SENSITIZER AND OTHER ANTI-DIABETIC AGENTS
EA200300323A1 (en) DERIVATIVES OF GUANIDININOBENZAMIDE (OPTIONS), COMPOSITION (OPTIONS), METHOD OF TREATMENT OF MEDIATED DISTRIBUTIONS mc4-r
BR0009864A (en) Compound, pharmaceutical composition, methods for the treatment of diseases, for the treatment and / or prevention of conditions mediated by nuclear receptors and for the treatment and / or prevention of diabetes and / or obesity, and, use of a compound
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
UY24543A1 (en) MESYLATE SALT 5- (2- (4- (1,2-BENZOISOTIAZOL- 3-IL) -1-PIPERAZINYL) ETHYL) -6-CHLORINE-1,3-DIHYDRO-2H-INDOL-2-ONA
DE69530094D1 (en) THIAZOLIDINDIONE DERIVATIVES, THEIR PRODUCTION AND USE
ATE420090T1 (en) CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
CY1107500T1 (en) USE OF FLUMAZENIL IN THE DEVELOPMENT OF A DRUG FOR THE ALTERNATIVE TREATMENT OF ALCOHOL ADDICTION
KR930702287A (en) New compound
CO5440230A1 (en) NEW HETEROCICLIC COMPOUND INCLUDING TETRAHYDROISOQUINOLINE AND A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME
PE20010580A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT DIABETES
RU2008126389A (en) DERIVATIVES OF 1,1-DIOXOTHIOMORPHOLINYLINDOLYLMYL METHANONE FOR USE AS HISTAMINASE (H3) MODULATORS
AR043259A1 (en) METHOD FOR THE TREATMENT OF SEVERE CARDIAC INSUFFICIENCY AND MEDICATION FOR IT
KR960700696A (en) 5-HT2RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS
EA200601144A1 (en) TABLET OF SLOW-DOWN PREVENTION OF INSULIN SENSITIZER TO INSULIN
AR012997A1 (en) USE OF 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] THIAZOLIDIN-2,4- DIONA AND INSULIN FOR THE PREPARATION OF MEDICINES, AND CONTAINING PHARMACEUTICAL COMPOSITION.
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
DE50312523D1 (en) Pharmaceutical Composition and its use
KR880007462A (en) Propiophenone Derivatives for the Treatment of Frequency
KR910007911A (en) Benzocycloalkylaminopyridineamine and related compounds, methods for their preparation and their use as intermediates and medicaments
RU2005141559A (en) METHOD FOR TREATING AND PREVENTING SYMPTOMS OF THE LOWER DEPARTMENT OF THE URINE

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed